Is Alterity Therapeutics Limited (NASDAQ:ATHE) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Alterity Therapeutics Limited at current levels.
A $70M binary bet on the first drug that meaningfully alters Multiple System Atrophy, with Phase 3 readiness as the re-rating fuse.
Where ATHE is headed
Multiple System Atrophy kills patients within 6-10 years of diagnosis. There is no approved disease-modifying therapy. Nothing. That vacuum is what makes Alterity Therapeutics (NASDAQ:ATHE) an asymmetric wager rather than a lottery ticket, and it is why a $70 million market cap in September 2026 looks like the market pricing this as a binary that has already failed. It hasn't. The ATH434-201 Phase 2 readout in mid-2024 hit clinically meaningful separation on the modified UMSARS scale and showed biomarker movement on iron accumulation in the substantia nigra, which is exactly the mechanism Alterity has been chasing since the Prana days. By late 2027, if the company can secure a Phase 3 partnership or non-dilutive funding pathway with EMA and FDA alignment on a registration-enabling trial design, the equity story shifts from 'orphan neuro biotech burning cash' to 'the only company with human proof-of-concept in a disease where every other program has failed.'
Read the full Compass Direction on ATHE
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $3.07).
See the full ATHE analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Alterity Therapeutics Limited (NASDAQ:ATHE) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Alterity Therapeutics Limited at current levels. A $70M binary bet on the first drug that meaningfully alters Multiple System Atrophy, with Phase 3 readiness as the re-rating fuse.
What is ATHE's Compass Score?
Alterity Therapeutics Limited scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for ATHE?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ATHE page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.